Legal & General Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.22B Buy
43,505,563
+641,338
+1% +$17.1M 0.28% 64
2025
Q4
$1.07B Buy
42,864,225
+1,123,039
+3% +$28.3M 0.24% 73
2025
Q3
$1.06B Buy
41,741,186
+3,296,415
+9% +$81.4M 0.24% 75
2025
Q2
$932M Buy
38,444,771
+1,384,227
+4% +$32.3M 0.23% 74
2025
Q1
$939M Buy
37,060,544
+153,979
+0.4% +$4.03M 0.26% 72
2024
Q4
$979M Sell
36,906,565
-955,377
-3% -$25.9M 0.26% 62
2024
Q3
$1.1B Buy
37,861,942
+702,070
+2% +$20.5M 0.29% 53
2024
Q2
$1.04B Sell
37,159,872
-3,859,034
-9% -$106M 0.29% 54
2024
Q1
$1.14B Sell
41,018,906
-513,451
-1% -$14.2M 0.33% 50
2023
Q4
$1.2B Sell
41,532,357
-979,118
-2% -$29.6M 0.37% 41
2023
Q3
$1.41B Sell
42,511,475
-1,329,245
-3% -$47M 0.49% 30
2023
Q2
$1.61B Buy
43,840,720
+2,093,282
+5% +$81.5M 0.52% 27
2023
Q1
$1.7B Buy
41,747,438
+614,632
+1% +$26.5M 0.61% 24
2022
Q4
$2.11B Sell
41,132,806
-681,703
-2% -$32.7M 0.81% 18
2022
Q3
$1.83B Sell
41,814,509
-977,163
-2% -$47.5M 0.71% 19
2022
Q2
$2.24B Buy
42,791,672
+1,336,403
+3% +$68.1M 0.79% 14
2022
Q1
$2.15B Buy
41,455,269
+2,866,750
+7% +$149M 0.65% 17
2021
Q4
$2.28B Sell
38,588,519
-291,953
-0.8% -$14.5M 0.69% 16
2021
Q3
$1.67B Buy
38,880,472
+1,486,959
+4% +$65.9M 0.54% 23
2021
Q2
$1.46B Buy
37,393,513
+1,434,331
+4% +$55.8M 0.49% 28
2021
Q1
$1.3B Sell
35,959,182
-539,252
-1% -$19.1M 0.49% 32
2020
Q4
$1.34B Sell
36,498,434
-1,922,211
-5% -$70.5M 0.53% 29
2020
Q3
$1.34B Sell
38,420,645
-558,616
-1% -$19.6M 0.6% 24
2020
Q2
$1.21B Buy
38,979,261
+295,599
+0.8% +$10M 0.58% 26
2020
Q1
$1.2B Buy
38,683,662
+929,791
+2% +$31.7M 0.7% 20
2019
Q4
$1.4B Buy
37,753,871
+926,829
+3% +$33M 0.67% 24
2019
Q3
$1.26B Buy
36,827,042
+611,347
+2% +$22.2M 0.66% 27
2019
Q2
$1.49B Sell
36,215,695
-437,401
-1% -$17.4M 0.8% 18
2019
Q1
$1.48B Buy
36,653,096
+5,595,890
+18% +$224M 0.84% 17
2018
Q4
$1.29B Buy
31,057,206
+1,889,229
+6% +$78.4M 1% 12
2018
Q3
$1.22B Buy
29,167,977
+326,548
+1% +$12.6M 0.87% 12
2018
Q2
$993M Sell
28,841,429
-1,929,613
-6% -$65.9M 0.77% 20
2018
Q1
$1.04B Sell
30,771,042
-2,135,171
-6% -$73.4M 0.79% 18
2017
Q4
$1.13B Sell
32,906,213
-655,774
-2% -$22.4M 0.82% 18
2017
Q3
$1.14B Buy
33,561,987
+399,687
+1% +$12.8M 0.85% 17
2017
Q2
$1.06B Buy
33,162,300
+308,652
+0.9% +$9.73M 0.85% 18
2017
Q1
$1.07B Buy
32,853,648
+1,231,115
+4% +$38.8M 0.9% 17
2016
Q4
$974M Buy
31,622,533
+239,768
+0.8% +$7.32M 0.91% 17
2016
Q3
$1.01B Buy
31,382,765
+77,509
+0.2% +$2.59M 1.02% 15
2016
Q2
$1.05B Buy
31,305,256
+332,628
+1% +$10.6M 1.1% 14
2016
Q1
$871M Buy
30,972,628
+514,557
+2% +$14.7M 0.96% 17
2015
Q4
$933M Buy
30,458,071
+62,021
+0.2% +$1.95M 1.05% 15
2015
Q3
$906M Buy
30,396,050
+775,242
+3% +$24.9M 1.1% 10
2015
Q2
$942M Buy
29,620,808
+45,952
+0.2% +$1.5M 1.11% 10
2015
Q1
$976M Sell
29,574,856
-596,254
-2% -$19M 1.17% 8
2014
Q4
$892M Sell
30,171,110
-779,388
-3% -$22.3M 1.05% 13
2014
Q3
$868M Sell
30,950,498
-2,037,875
-6% -$57.2M 1.04% 13
2014
Q2
$929M Buy
32,988,373
+248,629
+0.8% +$7.09M 1.08% 13
2014
Q1
$998M Sell
32,739,744
-1,009,009
-3% -$30.1M 1.21% 11
2013
Q4
$981M Sell
33,748,753
-349,473
-1% -$10.2M 1.19% 11
2013
Q3
$929M Sell
34,098,226
-2,007,576
-6% -$54.6M 1.22% 11
2013
Q2
$960M Buy
+36,105,802
New +$998M 1.33% 10

Other funds holding PFE

Legal & General Group's PFE Position: Q1 2026 in Review

Legal & General Group increased its Pfizer (PFE) stake by 1.5% in Q1 2026, buying an estimated $17.1M and bringing the position to 43,505,563 shares worth $1.22B. The position accounts for 0.28% of the portfolio, ranked #64.

Legal & General Group first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.28B in Q4 2021. 2,938 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Legal & General Group held 43,505,563 shares of Pfizer worth $1.22B as of Q1 2026.
  • Legal & General Group bought 641,338 Pfizer shares in Q1 2026, an estimated $17.1M.
  • Pfizer made up 0.28% of Legal & General Group's portfolio in Q1 2026, its #64 holding.
  • Legal & General Group first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Legal & General Group's Pfizer position peaked at $2.28B in Q4 2021.
  • 2,938 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.